CCDC50

Across TCGA pan-cancer cohorts, CCDC50 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CCDC50’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CCDC50 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CCDC50 is over-expressed in tumor, although a few such as LUAD and COAD show the opposite, repressed pattern.

CCRCC, LUAD, and COAD are the cancer types where CCDC50 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCDC50 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+0.490	<.001	11	view →
LUAD	Female	III,IV	−0.602	<.001	9	view →
COAD	Male	III,IV	−0.539	<.001	9	view →
LSCC	Male	III,IV	−0.351	<.001	8	view →
PDAC	All	All	+0.245	<.001	4	view →
HNSC	All	All	+0.117	.012	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CCDC50–CCRCC

Open the CCRCC breakdown →